OBJECTIVES: The purpose of this study is to evaluate the stem cell mobilization capacity, anti-tumor effect, and feasibility of ifosfamide/carboplatin/etoposide (ICE) for transplant-eligible patients with medulloblastoma. MATERIALS AND METHODS: Six patients (23 months to 18 years old) with high-risk or relapsed medulloblastoma received one cycle of ICE, which consisted of ifosfamide at 1.8 g/m(2) for 5 days, carboplatin 400 mg/m(2) for 2 days, and etoposide 100 mg/m(2) for 5 days. Stem cells were mobilized with ICE followed by granulocyte colony-stimulating factor at 10 microg kg(-1) day(-1). RESULTS: After one cycle of ICE, the median number of harvested CD34+ cells per apheresis session was 11.85 x 10(6) cells/kg (range, 0.2 to 71.2 x 10(6) cells/kg). Two patients obtained a complete response and three patients a partial response. All patients experienced severe myelosuppression, and three infectious toxicities were observed. CONCLUSIONS: These results suggest that ICE is optimal for mobilizing stem cells, effective for high-risk or relapsed medulloblastoma, and tolerable with limited non-hematological toxicity.
OBJECTIVES: The purpose of this study is to evaluate the stem cell mobilization capacity, anti-tumor effect, and feasibility of ifosfamide/carboplatin/etoposide (ICE) for transplant-eligible patients with medulloblastoma. MATERIALS AND METHODS: Six patients (23 months to 18 years old) with high-risk or relapsed medulloblastoma received one cycle of ICE, which consisted of ifosfamide at 1.8 g/m(2) for 5 days, carboplatin 400 mg/m(2) for 2 days, and etoposide 100 mg/m(2) for 5 days. Stem cells were mobilized with ICE followed by granulocyte colony-stimulating factor at 10 microg kg(-1) day(-1). RESULTS: After one cycle of ICE, the median number of harvested CD34+ cells per apheresis session was 11.85 x 10(6) cells/kg (range, 0.2 to 71.2 x 10(6) cells/kg). Two patients obtained a complete response and three patients a partial response. All patients experienced severe myelosuppression, and three infectious toxicities were observed. CONCLUSIONS: These results suggest that ICE is optimal for mobilizing stem cells, effective for high-risk or relapsed medulloblastoma, and tolerable with limited non-hematological toxicity.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: A M Abu-Ghosh; M D Krailo; S C Goldman; R S Slack; V Davenport; E Morris; J H Laver; G H Reaman; M S Cairo Journal: Ann Oncol Date: 2002-03 Impact factor: 32.976
Authors: Patrick Van Winkle; Anne Angiolillo; Mark Krailo; Ying-Kuen Cheung; Barry Anderson; Virginia Davenport; Gregory Reaman; Mitchell S Cairo Journal: Pediatr Blood Cancer Date: 2005-04 Impact factor: 3.167
Authors: N L Kobrinsky; R J Packer; J M Boyett; P Stanley; T Shiminski-Maher; J C Allen; J H Garvin; D J Stewart; J L Finlay Journal: J Neurooncol Date: 1999 Impact factor: 4.130
Authors: P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: R L Heideman; E H Kovnar; S J Kellie; E C Douglass; A J Gajjar; A W Walter; J A Langston; J J Jenkins; Y Li; C Greenwald Journal: J Clin Oncol Date: 1995-09 Impact factor: 44.544
Authors: Alexander K Yuile; Marina Kastelan; Adrian Ps Lee; Michael Back; James Drummond; Helen R Wheeler Journal: Oxf Med Case Reports Date: 2022-03-16